ABBVIE INC (4AB.DE) Stock Fundamental Analysis
Europe - FRA:4AB - US00287Y1091 - Common Stock
205 EUR
+10.8 (+5.56%)
Overall 4AB gets a fundamental rating of 5 out of 10. We evaluated 4AB against 74 industry peers in the Biotechnology industry. There are concerns on the financial health of 4AB while its profitability can be described as average. 4AB has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
4AB had positive earnings in the past year.
In the past year 4AB had a positive cash flow from operations.
Each year in the past 5 years 4AB has been profitable.
Each year in the past 5 years 4AB had a positive operating cash flow.
1.2 Ratios
The Return On Assets of 4AB (2.71%) is better than 77.03% of its industry peers.
The Return On Invested Capital of 4AB (13.81%) is better than 90.54% of its industry peers.
4AB had an Average Return On Invested Capital over the past 3 years of 13.67%. This is in line with the industry average of 12.80%.
The 3 year average ROIC (13.67%) for 4AB is below the current ROIC(13.81%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.71% | ||
| ROE | N/A | ||
| ROIC | 13.81% |
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
1.3 Margins
4AB has a better Profit Margin (6.38%) than 81.08% of its industry peers.
4AB's Profit Margin has declined in the last couple of years.
4AB's Operating Margin of 31.27% is amongst the best of the industry. 4AB outperforms 90.54% of its industry peers.
4AB's Operating Margin has declined in the last couple of years.
4AB has a better Gross Margin (70.93%) than 63.51% of its industry peers.
In the last couple of years the Gross Margin of 4AB has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.27% | ||
| PM (TTM) | 6.38% | ||
| GM | 70.93% |
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), 4AB is creating some value.
4AB has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, 4AB has more shares outstanding
4AB has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.49 indicates that 4AB is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of 4AB (2.49) is better than 71.62% of its industry peers.
The Debt to FCF ratio of 4AB is 3.86, which is a good value as it means it would take 4AB, 3.86 years of fcf income to pay off all of its debts.
4AB has a Debt to FCF ratio of 3.86. This is amongst the best in the industry. 4AB outperforms 81.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.86 | ||
| Altman-Z | 2.49 |
ROIC/WACC1.68
WACC8.21%
2.3 Liquidity
A Current Ratio of 0.74 indicates that 4AB may have some problems paying its short term obligations.
4AB has a worse Current ratio (0.74) than 78.38% of its industry peers.
A Quick Ratio of 0.61 indicates that 4AB may have some problems paying its short term obligations.
4AB has a Quick ratio of 0.61. This is in the lower half of the industry: 4AB underperforms 79.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.74 | ||
| Quick Ratio | 0.61 |
3. Growth
3.1 Past
The earnings per share for 4AB have decreased strongly by -12.09% in the last year.
4AB shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 2.51% yearly.
4AB shows a small growth in Revenue. In the last year, the Revenue has grown by 3.71%.
Measured over the past years, 4AB shows a quite strong growth in Revenue. The Revenue has been growing by 11.11% on average per year.
EPS 1Y (TTM)-12.09%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%-38%
Revenue 1Y (TTM)3.71%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%9.1%
3.2 Future
The Earnings Per Share is expected to grow by 13.65% on average over the next years. This is quite good.
Based on estimates for the next years, 4AB will show a small growth in Revenue. The Revenue will grow by 7.31% on average per year.
EPS Next Y6.31%
EPS Next 2Y19.75%
EPS Next 3Y16.76%
EPS Next 5Y13.65%
Revenue Next Year8.37%
Revenue Next 2Y8.77%
Revenue Next 3Y8.33%
Revenue Next 5Y7.31%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
4AB is valuated quite expensively with a Price/Earnings ratio of 25.22.
4AB's Price/Earnings ratio is rather cheap when compared to the industry. 4AB is cheaper than 82.43% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 25.91, 4AB is valued at the same level.
4AB is valuated correctly with a Price/Forward Earnings ratio of 16.41.
Compared to the rest of the industry, the Price/Forward Earnings ratio of 4AB indicates a rather cheap valuation: 4AB is cheaper than 91.89% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of 4AB to the average of the S&P500 Index (34.57), we can say 4AB is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.22 | ||
| Fwd PE | 16.41 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 4AB indicates a somewhat cheap valuation: 4AB is cheaper than 79.73% of the companies listed in the same industry.
85.14% of the companies in the same industry are more expensive than 4AB, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 23.07 | ||
| EV/EBITDA | 18.08 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of 4AB may justify a higher PE ratio.
A more expensive valuation may be justified as 4AB's earnings are expected to grow with 16.76% in the coming years.
PEG (NY)4
PEG (5Y)10.04
EPS Next 2Y19.75%
EPS Next 3Y16.76%
5. Dividend
5.1 Amount
4AB has a Yearly Dividend Yield of 3.16%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 11.17, 4AB pays a better dividend. On top of this 4AB pays more dividend than 97.30% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.36, 4AB pays a bit more dividend than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.16% |
5.2 History
The dividend of 4AB is nicely growing with an annual growth rate of 7.72%!
Dividend Growth(5Y)7.72%
Div Incr Years4
Div Non Decr Years4
5.3 Sustainability
304.54% of the earnings are spent on dividend by 4AB. This is not a sustainable payout ratio.
4AB's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP304.54%
EPS Next 2Y19.75%
EPS Next 3Y16.76%
FRA:4AB (11/13/2025, 7:00:00 PM)
205
+10.8 (+5.56%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners74.42%
Inst Owner ChangeN/A
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap362.14B
Revenue(TTM)56.33B
Net Income(TTM)3.72B
Analysts78.92
Price Target208.81 (1.86%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.16% |
Yearly Dividend5.4
Dividend Growth(5Y)7.72%
DP304.54%
Div Incr Years4
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.04%
Min EPS beat(2)0.95%
Max EPS beat(2)1.14%
EPS beat(4)4
Avg EPS beat(4)0.75%
Min EPS beat(4)0.02%
Max EPS beat(4)1.14%
EPS beat(8)7
Avg EPS beat(8)0.76%
EPS beat(12)9
Avg EPS beat(12)0.46%
EPS beat(16)11
Avg EPS beat(16)0.4%
Revenue beat(2)2
Avg Revenue beat(2)0.93%
Min Revenue beat(2)0.63%
Max Revenue beat(2)1.23%
Revenue beat(4)2
Avg Revenue beat(4)0.24%
Min Revenue beat(4)-0.71%
Max Revenue beat(4)1.23%
Revenue beat(8)4
Avg Revenue beat(8)0.36%
Revenue beat(12)5
Avg Revenue beat(12)-0.32%
Revenue beat(16)5
Avg Revenue beat(16)-0.81%
PT rev (1m)6.23%
PT rev (3m)12.94%
EPS NQ rev (1m)-45.74%
EPS NQ rev (3m)-45.37%
EPS NY rev (1m)-12.28%
EPS NY rev (3m)-13.15%
Revenue NQ rev (1m)0.02%
Revenue NQ rev (3m)0.95%
Revenue NY rev (1m)0.14%
Revenue NY rev (3m)1.18%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.22 | ||
| Fwd PE | 16.41 | ||
| P/S | 7.21 | ||
| P/FCF | 23.07 | ||
| P/OCF | 21.82 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 18.08 |
EPS(TTM)8.13
EY3.97%
EPS(NY)12.49
Fwd EY6.09%
FCF(TTM)8.89
FCFY4.33%
OCF(TTM)9.39
OCFY4.58%
SpS28.42
BVpS-0.09
TBVpS-45.24
PEG (NY)4
PEG (5Y)10.04
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.71% | ||
| ROE | N/A | ||
| ROCE | 18.72% | ||
| ROIC | 13.81% | ||
| ROICexc | 14.74% | ||
| ROICexgc | 370.81% | ||
| OM | 31.27% | ||
| PM (TTM) | 6.38% | ||
| GM | 70.93% | ||
| FCFM | 31.27% |
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
ROICexc(3y)15.06%
ROICexc(5y)13.91%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)17.54%
ROCE(5y)16.27%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-1.81%
ROICexc growth 5Y-14.87%
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
F-Score6
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.86 | ||
| Debt/EBITDA | 2.58 | ||
| Cap/Depr | 12.62% | ||
| Cap/Sales | 1.79% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 72.74% | ||
| Profit Quality | 489.9% | ||
| Current Ratio | 0.74 | ||
| Quick Ratio | 0.61 | ||
| Altman-Z | 2.49 |
F-Score6
WACC8.21%
ROIC/WACC1.68
Cap/Depr(3y)9.59%
Cap/Depr(5y)10.06%
Cap/Sales(3y)1.45%
Cap/Sales(5y)1.5%
Profit Quality(3y)361.43%
Profit Quality(5y)328.91%
High Growth Momentum
Growth
EPS 1Y (TTM)-12.09%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%-38%
EPS Next Y6.31%
EPS Next 2Y19.75%
EPS Next 3Y16.76%
EPS Next 5Y13.65%
Revenue 1Y (TTM)3.71%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%9.1%
Revenue Next Year8.37%
Revenue Next 2Y8.77%
Revenue Next 3Y8.33%
Revenue Next 5Y7.31%
EBIT growth 1Y13.81%
EBIT growth 3Y-5.38%
EBIT growth 5Y3.87%
EBIT Next Year20.95%
EBIT Next 3Y15.22%
EBIT Next 5Y11.09%
FCF growth 1Y-26.45%
FCF growth 3Y-6.75%
FCF growth 5Y6.9%
OCF growth 1Y-24.5%
OCF growth 3Y-6.19%
OCF growth 5Y7.14%
ABBVIE INC / 4AB.DE FAQ
What is the ChartMill fundamental rating of ABBVIE INC (4AB.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to 4AB.DE.
What is the valuation status of ABBVIE INC (4AB.DE) stock?
ChartMill assigns a valuation rating of 6 / 10 to ABBVIE INC (4AB.DE). This can be considered as Fairly Valued.
How profitable is ABBVIE INC (4AB.DE) stock?
ABBVIE INC (4AB.DE) has a profitability rating of 6 / 10.
What are the PE and PB ratios of ABBVIE INC (4AB.DE) stock?
The Price/Earnings (PE) ratio for ABBVIE INC (4AB.DE) is 25.22 and the Price/Book (PB) ratio is -2299.32.
Can you provide the expected EPS growth for 4AB stock?
The Earnings per Share (EPS) of ABBVIE INC (4AB.DE) is expected to grow by 6.31% in the next year.